Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has received an average rating of “Hold” from the fourteen research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating on the company.
Several analysts have issued reports on BAYRY shares. Morgan Stanley restated an “overweight” rating on shares of Bayer Aktiengesellschaft in a research note on Friday, January 8th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Bayer Aktiengesellschaft in a research note on Thursday, November 5th. Barclays reiterated an “equal weight” rating on shares of Bayer Aktiengesellschaft in a research note on Wednesday, February 10th. Nord/LB reiterated a “buy” rating on shares of Bayer Aktiengesellschaft in a research note on Wednesday, January 6th. Finally, Credit Suisse Group reiterated a “neutral” rating on shares of Bayer Aktiengesellschaft in a research note on Wednesday, January 20th.
Shares of BAYRY traded up $0.06 during mid-day trading on Tuesday, hitting $16.34. The stock had a trading volume of 275,964 shares, compared to its average volume of 575,837. The firm has a market cap of $60.95 billion, a P/E ratio of -6.10, a PEG ratio of 6.10 and a beta of 1.34. The business has a fifty day moving average price of $15.99 and a 200-day moving average price of $15.09. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.10 and a quick ratio of 0.81. Bayer Aktiengesellschaft has a 52 week low of $11.65 and a 52 week high of $21.05.
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
See Also: Buy-Side Analysts
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.